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NASA and private spacefaring companies plan 
to send exploration missions to mars within the 
next two decades. The environment of space, 
duration of the mission, distance from earth, 
and limited available resources present 
significant challenges for the provision of health 
care. It has been estimated that at least one 
medical emergency is likely to occur during 
such a mission, which may necessitate surgical 
treatment, and therefore anaesthesia. The 
provision of safe anaesthesia faces challenges 
arising from physiological adaptations to 
space, difficulty achieving and maintaining 
personnel expertise, possible pharmacological 
changes in anaesthetic agents used, limited 
consumable shelf-life and provision of 
intravenous fluids and blood products. In this 
review article we discuss these challenges in 
the context of a hypothetical case. 
 
INTRODUCTION 
Since the middle of the 20th century, nations have 
been sending astronauts into space as the new 
frontier for exploration. The turn of the century has 
seen a groundswell of interest from national and 
private bodies in sending a crewed Exploration 
Class Mission to Mars. NASA has stated plans to 
send a crew of “at least 4” on a mission of “at least 
900 days” to Mars, and private companies such as 
the MarsOne Project and SpaceX have expressed 
similar goals(1, 2). A mission to Mars presents 
challenges that have never been faced, including 
the management of a medical or surgical 
emergency on board. Models used to calculate the 
likelihood of such an emergency suggest that 
there is likely to be at least one on a 900 day 
flight(3-5). A medical emergency on board carries 
a significant risk of morbidity or mortality, as well 
as risk to the mission itself. 
Broadly, the challenge of managing a medical 
emergency in space is three-fold. Firstly, 
resources are likely to be limited. Weight 
restrictions on payload would likely mean that 
some simple medical consumables (e.g. 
crystalloid fluids) would be impractical. 
Radiological and pathological diagnostic support 
is also unavailable, except for ultrasound(6-8). 
Secondly, there is likely to be a lack of skilled 
personnel on board. It has been suggested that 
the most appropriate Medical Officer would be an 
emergency physician with broad surgical skills and 
wilderness medicine training(9, 10), but it is 
possible that the Crew Medical Officer (CMO) 
would be a specialist in another field with only 
basic medical training. Finally, timely evacuation 
to a terrestrial medical centre is impossible. 
Evacuation from Mars to Earth would take 9-12 
months, and depending on the relative locations of 
the planets, communication between Earth and 
Mars could take as long as 20 minutes in each 
direction(3), making telemedicine impractical. 
These challenges mean that the emergency will 
have to be dealt with in its entirety by the crew, 
using only the resources on board the vehicle.   
 
A HYPOTHETICAL CASE 
To illustrate the challenges posed by an 
emergency, we will discuss the hypothetical case 
of Dr FH, 35 year old male, PhD (Astrophysics). 
On day 700 of a 900 day mission to Mars, Dr FH 
develops acute central abdominal pain which 
migrates to the right iliac fossa, fever, anorexia 
and vomiting. Having undergone extensive 
medical screening as part of his selection and 
training as an astronaut, Dr FH is otherwise 
healthy, with no significant medical or surgical 
history. His appendix is still in situ. 
 
Dr FH has a low risk for less common causes of 
this presentation, such as caecal diverticulitis or 
inflammatory bowel disease, but the diagnosis is 
not simple. The lack of diagnostic imaging or 
pathology services means that the diagnosis must 
be purely clinical (with the possible assistance of 
ultrasound), and possibly made by a non-
physician, depending on the composition of the 
crew.  
The CMO decides that, clinically, Dr FH has acute 
appendicitis. We acknowledge that the benefits 
and risks prophylactic appendicectomy is currently 
being debated(11, 12), but this topic will not be 
discussed here. Appendicitis occurs in healthy 
adults, with a lifetime risk of 8.6 percent in males, 
and 6.9 percent in females(13). The current 
standard of practice for acute appendicitis is 
laparoscopic appendicectomy(14). 
In this case, non-operative management with 
empiric antibiotics and intravenous fluid 
replacement might be a preferred strategy to avoid 
surgery in space. However, this approach carries 
the risk of clinical deterioration requiring rescue 
appendicectomy, as well as perforation, abscess 
formation and peritonitis(11-14). The challenges of 
providing the intravenous fluids (crystalloid or 
blood products) required for intravenous 
antibiotics to be administered in space will be 
discussed later. Despite the attendant risks, non-
operative management may be an option as it may 
delay the need for appendicectomy until the crew 
has returned to Earth.  
Concerned about the risk of failure of conservative 
management and difficulty in managing a 
deteriorating clinical situation with 200 days 
remaining on the mission, the CMO and Dr FH 
elect to perform an appendicectomy.  For this 
paper, we will assume that the CMO has 
appropriate equipment, training and clinical aids to 
perform the surgical procedure. 
EXISTING LITERATURE 
There is a growing body of literature describing 
surgical techniques that could be used in 
microgravity, including laparotomy and 
laparoscopy(15-17). The need for surgery implies 
the need for anaesthesia, but there is 
comparatively little evidence on the use of 
anaesthesia in a weightless environment.  
 
Anaesthesia in microgravity analogues 
To date, research on anaesthesia of humans has 
been limited to space analogues. The 
disadvantage of this approach is that there is not 
perfect way to simulate microgravity on earth. 
Modern analogues simulate only a single aspect 
of the environment, such as microgravity 
(parabolic flight, neutral buoyancy studies), 
physiological adaptations (head down bed rest), or 
resource limitations. Some minor procedures 
which would be required for anaesthetic delivery in 
space have been demonstrated, such as 
venepuncture of the antecubital fossa(18) and 
visualisation of thoracic, cardiac, vascular, ocular 
and joint structures with ultrasound(6-8). 
A few studies have demonstrated airway 
management in microgravity analogues. 
Endotracheal intubation has been demonstrated in 
neutral buoyancy (19) and parabolic flight (20) 
using simulation models. These studies 
demonstrated the difficulty of intubation of an 
unrestrained patient, and the difficulty of the skill 
when performed by novice practitioners. 
Laryngeal Mask Airway (LMA) insertion in 
parabolic flight has also been demonstrated.  
 
Pharmacokinetic changes in space and 
microgravity analogues 
A review article by Kast et al. (21) details the 
limited body of research into pharmacokinetic 
changes caused by adaptation to microgravity. 
The two pharmacokinetic studies conducted on 
subjects in space (22, 23) were limited by sample 
size and did not show a consistent effect. Four 
studies examining the pharmacokinetic changes 
following intravenous administration have been 
conducted, but these data are difficult to interpret 
owing to small sample sizes, inconsistent 
techniques of simulating microgravity (supine 
position vs 6 head down bed rest [HDBR]) and 
poor precision of measurements. Seubert et al. 
(24) studied pharmacokinetic changes of propofol 
in patients following 48 hours of HDBR, and 
showed a small decrease in clearance, which may 
be clinically insignificant, however it is unclear how 
well HDBR simulates the effect of microgravity on 
pharmacokinetics, and this study was limited by its 
small sample size and lack of surgical stimulus. 
Further research is required before definite 
conclusions can be made regarding 
pharmacokinetic changes in anaesthetic drugs. 
 
 
APPROACH TO ANAESTHESIA 
It should be noted that there are two broad 
approaches to anaesthesia which are being 
considered for use in an exploration class mission 
to mars. These are general anaesthesia and 
regional anaesthesia. In the case of Dr FH, 
general anaesthesia will be most likely required for 
intra-abdominal surgery, and this would also be 
true for surgical approaches to other conditions 
where regional anaesthesia is not feasible. In 
general, however, regional anaesthesia is likely to 
be the preferred option when available. The “Local 
and Vocal” approach maintains the homeostatic 
and protective reflexes, reducing the risk of 
aspiration or cardiovascular complications which 
may be associated with general anaesthesia. It will 
also allow the crew member to remain awake 
during the procedure, and recover quickly 
afterwards. However, whichever anaesthetic 
approach is used, it is likely to be complicated by 
physiological and pharmacological changes due to 
microgravity. 
 
PHYSIOLOGICAL CHANGES IN MICROGRAVITY 
The effect of microgravity on human physiology 
has implications for the conduct of surgery and 
anaesthesia in space. Among all the adaptations, 
there are four that are directly relevant to 
anaesthesia: reduction in blood volume, changes 
in cardiac systolic and diastolic function, 
musculoskeletal wasting and changes in the 
neuromuscular junction, and slowed 
gastrointestinal motility and gastric emptying. 
 
Cardiovascular changes 
When standing at sea level, circulating blood is 
pulled towards the legs, resulting in a mean-
arterial-pressure gradient across the body. In a 
microgravity environment, the gravitational force 
creating this gradient is not present, and thus 
pressures equalise throughout the body(3, 25-27). 
This results in redistribution of blood volume from 
the legs to the torso and head. The apparent 
increased circulatory volume results in diuresis 
and contraction of blood volume by around 10-
15% within the first week in space(3, 25-27). This 
is accompanied by cardiac atrophy and a 
reduction in cardiac output of 17-20%. 
Komorowski et al. (3) describe the cardiovascular 
adaptations in detail. The combination of these 
factors is likely to result in increased risk of 
arrhythmia and reduced capacity to compensate 
for haemorrhage or reduction in peripheral 
resistance(3, 9, 28, 29). The movement of blood 
volume in a cephalad direction also produces 
facial oedema, which could potentially complicate 




The loss of bone and muscle mass in microgravity 
environments has been well documented(30) and 
known since the early days of space flight. Modern 
astronauts can maintain bone density through 
exercise but may still be prone to fracture due to 
poor bone quality. Exercise programs in space 
have helped astronauts in maintaining muscular 
endurance, but skeletal and cardiac muscle 
atrophy in space remains a problem(3). Disease 
models in humans that also display skeletal 
muscle atrophy (e.g. Guillain Barré (29)), and 
microgravity analogue studies in animals(31, 32) 
suggest that acetylcholine receptor changes may 
accompany skeletal muscle atrophy. This implies 
a risk of hyperkalaemia following administration of 
Suxamethonium to astronauts in space(3, 28, 29), 
and excludes Suxamethonium as an agent for use 
in rapid sequence induction. In addition to muscle 
atrophy, changed in fat deposition may impact the 
pharmacokinetics of anaesthetic drugs by 




It has been suggested that gastric emptying is 
slowed in the first 72 hours of space flight, possibly 
due to space motion sickness(3, 5, 33). Two 
spaceflight studies have shown variable 
absorption of paracetamol, used as a marker of 
gastric emptying(21-23). This has implications for 
in-flight anaesthesia, as any delay in gastric 
emptying increases the risk of regurgitation and 
aspiration following induction of anaesthesia, as 







The exact composition of the crew for a mission to 
Mars is unknown, but a diverse range of skills and 
specialties are required to operate the various 
systems. There is a history of physicians in the 
crew of the International Space Station (ISS) (34). 
However, there is no requirement that the CMO is 
a physician. In the case that the CMO is a 
physician, it is also possible that they do not have 
expertise in the anaesthetic skill set unless their 
background is in emergency medicine or 
anaesthetics. Anaesthesia in austere and 
resource poor environments (such as low-to-
middle income countries) or in isolated or confined 
environments, suggest that anaesthesia can be 
provided by non-medically trained personnel(35). 
However, the capacity to deal with complex cases 
will be limited. Komorowski et al. suggest that the 
ideal practitioner would be an emergency 
physician with surgical and wilderness medicine 
training(35). 
 
Intravenous cannulation with the administration of 
fluids has been demonstrated in weightlessness 
by non-physicians in parabolic flight 
simulations(18). Venepuncture of the anterior 
cubital fossa performed by astronauts on the ISS 
suggests that intravenous access would not be 
expected to be difficult. Intraosseous access 
devices could also be utilised, and a few studies 
suggest that induction of anaesthesia by this 
method is possible(36). 
 
Intubating laryngeal mask airway (ILMA) insertion 
has also been demonstrated in weightlessness by 
non-physicians in parabolic flight simulations. 
Endotracheal tube insertion (ETI) by anaesthetists 
in a neutral buoyancy environment has been 
shown to be difficult without restraint(19), and a 
study of ETI in parabolic flight by novice operators 
showed an unsatisfactory rate of correct 
placement and ventilation(20), but this result is 
difficult to interpret due to the extreme time 
restriction in parabolic flight. Laryngeal mask 
insertion has many favourable properties over ETI, 
which include ease and speed of use, elimination 
of the risk of oesophageal intubation, and lack of 
requirement for muscle relaxing agents(9). The 
risk of pulmonary aspiration of regurgitated gastric 
contents with an LMA in situ appears to be no 
higher than ETT. However this has only been 
observed in 1G, by trained anaesthetists with well 
fitting devices in well selected patients (37). 
Astronauts may be at increased risk of aspiration 
due to the possibility of delayed gastric emptying 
and increased gastrointestinal transit time(3, 5, 
33). In this case, ETI may be a preferred method 
of airway management, despite the other 
disadvantages. A recent study of rapid sequence 
induction including ETI in a Mars analogue 
environment demonstrated satisfactory ETI by 
non-physicians(38), but whether this skill can be 
satisfactorily transferred to a weightless 
environment remains to be demonstrated. The 
Clinical Outcome Metrics for Optimization of 
Robust Training (COMfORT) study commissioned 
by the National Space Biomedical Research 
Institute has also demonstrated that numerous 
medical procedures, including ETI, can be 
performed safely by non-physicians even up to 9 
months after initial training when provided Just-In-
Time training (39). 
 
The possibility of conducting regional anaesthesia 
in space has been discussed(3, 28, 40), and has 
significant benefits compared with general 
anaesthesia. These include the patient being 
conscious throughout the procedure (thus 
retaining access to their critical skillset), 
eliminating the need for muscle relaxation or 
airway management, rapid recovery, and good 
post-operative pain relief. It has been suggested 
that as few as three regional nerve block 
techniques would enable a wide array of limb 
surgery: Axillary, brachial, femoral, and subgluteal 
sciatic blocks(9). Identification of anatomical 
structures by ultrasound has been performed by 
astronauts on the ISS using the on-board 
ultrasound machine(6-8). It is therefore plausible 
that regional anaesthesia could be performed in 
space. However, this implies a significant training 
requirement for the crew. Depending on the 
technique in question, the number of procedures 
required to achieve an acceptable success rate 
can be a few as 20 (for femoral nerve blocks) or 
as many as 62 (in the case of axillary brachial 
blocks)(28). Once a crew member has been 
deemed competent, then skill maintenance 
becomes the challenge. However, just-in-time 
training may have a role in refreshing the required 
skill immediately before its performance(8, 39). 
Furthermore, all blocks carry a risk of failure, and 
failure of a block implies the need to perform the 
procedure under general anaesthetic. 
 
Pharmacological Considerations 
Physiological changes with microgravity may have 
an impact on the pharmacokinetics and 
pharmacodynamics of anaesthetic agents. Two 
pharmacokinetic studies have been performed in 
humans in space(22, 23), and there is a small 
body of literature investigating pharmacokinetic 
parameters of different medications in 
microgravity analogues(21, 24, 29, 33, 41-43). It is 
worth noting that volatile anaesthetic agents are 
not suitable agents for maintenance of general 
 
anaesthesia in space. The use of volatile 
anaesthetics in the closed environment would 
potentially expose the rest of the crew, and current 
vaporiser technology relies on gravity to separate 
the gas phase from the oily phase, and as such 
would not function in space(28, 40). Thus, total 
intravenous anaesthesia is required. 
Propofol is a very commonly used agent for 
induction and maintenance by Total Intravenous 
Anaesthesia (TIVA). It has the advantages of a 
rapid onset of action and is safe. Its undesirable 
effects include a reduction in total peripheral 
resistance and negative cardiac inotropy. The 
cardiovascular changes in microgravity of 
contraction of circulating volume, cardiac atrophy 
and reduction in cardiac output might predispose 
astronauts to hypotension following induction, 
requiring pressor therapy(28). One study of 
Propofol in subjects following 48h of head-down 
bed rest suggests that anaesthetic doses of 
Propofol in 1G and microgravity might be 
similar(24). However, the study was limited to 
anaesthesia only without a surgical stimulus, and 
the results have not been replicated in space. 
Furthermore, Propofol has an approximate volume 
of distribution of 70L and may be less impacted by 
contraction of circulating volume than anaesthetic 
agents with a lower volume of distribution, such as 
Ketamine, however reduction of total body volume 
by wasting of skeletal muscle may reduce the dose 
of Propofol required. It should also be noted that 
many conventional syringe drivers use a 
proprietary algorithm to maintain anaesthesia with 
TIVA by Propofol, and the algorithm uses a model 
which assumes a body composition and volume of 
distribution in 1G. These models may not be valid 
in the context of the physiological adaptations in 
microgravity. 
Ketamine is another anaesthetic agent which can 
be used for induction and maintenance of general 
anaesthesia. It has been suggested as an 
alternative anaesthetic agent for use in space due 
to some potential advantages, which include(28, 
29). 
• Favourable cardiovascular profile in 
patients with hypovolaemia 
• High therapeutic index compared to 
propofol 
• Rapid onset of action 
• Long shelf life in crystal form 
• Preservation of airway reflexes, 
maintenance of spontaneous ventilation, 
reduction in oxygen requirement 
• Multiple potential routes of administration 
Ketamine thus has numerous favourable 
properties in the hands of a non-physician 
anaesthetist in space. It carries much less risk of 
cardiovascular collapse, it minimises the 
requirement for definitive airway management 
(although the risk of vomiting requires access to 
an oropharyngeal suction device), the risk of lethal 
overdose is low, and its long shelf life means it is 
likely to remain in-date for the duration of the 
mission. This needs to be demonstrated in 
pharmacodynamics studies. The potential 
undesirable effects of Ketamine include 
emergence delirium, higher risk of post-operative 
nausea and vomiting and awareness, and its use 
in head injuries is controversial. While Ketamine is 
likely to have favourable pharmacodynamic 
properties in the context of physiological changes 
in microgravity, the pharmacokinetic changes are 
unknown. There is speculation that, due to its low 
volume of distribution of 3L, the pharmacokinetic 
profile of Ketamine may be more significantly 
impacted by the circulating volume contraction 
than Propofol. Further research is required if 
Ketamine is to be used as an anaesthetic agent in 
space.  
At least in the case of Dr FH, an open 
appendicectomy implies the requirement for 
muscle relaxation. It has been proposed that 
skeletal muscle atrophy in space could complicate 
the choice of paralytic agent(31, 32, 44-47). 
Skeletal muscle atrophy in disease analogues 
(such as Guillain Barré Syndrome) is 
accompanied by changes in neuromuscular 
junction nicotinic acetylcholine receptors(29). Use 
of a depolarising neuromuscular junction blocking 
agent (i.e. Suxamethonium) in this context is 
associated with a risk of hyperkalaemia and fatal 
cardiac arrhythmia(29). It is unknown whether this 
is also the case in astronauts. However, it seems 
prudent to exclude the use of Suxamethonium on 
this basis. Rocuronium may be the preferred 
neuromuscular junction blocking agent in space, 
due to its rapid onset of action at high doses(28) 





The planning parameters set by NASA in 2015 are 
that a mission to Mars would comprise a crew of 
“at least 4” and take “up to 1100 days”(1, 2). A 
 
mission of this duration implies significant 
logistical challenges for the medical consumables 
required for the provision of anaesthesia. An 1100 
day mission would require medications with a 
shelf-life exceeding that duration.  
 
In Australia, the shelf-life stated by manufacturers 
is limited by regulation to 3 years. This does not 
always reflect actual stability however, for 
example Ketamine can be formulated as an 
anhydrous crystal and has a shelf-life of about 20 
years(28), ideal for use in exploration class space 
missions. The manufacturers of Esmeron® 
(Rocuronium), Bridion® (Sugammadex) and 
Diprivan® (Propofol) were contacted for extended 
stability data beyond the stated year shelf life(48-
50). The manufacturer of Bridion® provided data 
on file for Bridion®, which confirmed the three year 
shelf-life(51). No extended stability data was made 
available for Esmeron(51). The manufacturer of 
Diprivan declined to provide extended stability 
data on the basis of confidentiality(52). A mission 
of 1100 days (which is within the timeframe NASA 
is planning for a mission to Mars(1, 2)) would 
exceed the shelf-life of each of the above 
formulations of Propofol, Rocuronium and 
Sugammadex.  
 
Furthermore, the environment of space appears to 
be more hostile to pharmaceuticals than Earth. 
Stability studies of medications returned from the 
ISS suggest that this shelf-life may be reduced 
(53, 54). Some medications returned for resupply 
from the ISS had degraded more than 10% of the 
active ingredient before the expiry date. The 
authors postulate that the high exposure to 
radiation in space may contribute to this enhanced 
degradation rate (53). This has significant 
implications for the viability of any medication on a 
long duration mission to Mars, and there is 
currently no available data on any of the 
anaesthetic medications being considered, which 
include local anaesthetics for regional 
anaesthesia. There is the potential that exposure 
to radiation may produce unusual degradation 
products which may be harmful on administration, 
rather than just ineffective, although no such 
products were identified in the studies. Further 
research is required to develop formulations with 
improved stability if these drugs are to be used to 
deliver anaesthesia in space.  
 
 
Intravenous Fluids and Blood Products 
Crystalloid intravenous fluids (e.g. normal saline, 
compound sodium lactate) are routinely used 
during surgery as maintenance fluid to prevent 
dehydration following fasting; for fluid resuscitation 
in hypovolaemia; and as a medium for delivery of 
intravenous infusion of drugs. Provision of 
crystalloid fluids in space is likely to be very 
expensive; in 2008, NASA estimated the cost of 
launching one pound of payload into orbit at 
USD$10,000(55), although the advent of private 
space transportation companies is likely to have 
reduced this figure through competition, and 
innovations like high-payload re-usable launch 
vehicles such as the SpaceX Falcon Heavy (56-
58). Each litre of crystalloid fluid weighs 
approximately 1kg or 2.2lb, thus “due to mass and 
volume limitations, space vehicles cannot carry 
sufficient IV fluid for medical contingencies”(59). 
NASA has developed a prototype IV fluids 
generation system for production of intravenous 
fluids in space, which generates purified water to 
be added to bags with pre-measured solutes to 
produce Normal Saline(59). Further research is 
required to determine if the product is suitable for 
medical use.  
In cases of hypovolaemia due to haemorrhage, 
blood products are the preferred means of volume 
resuscitation, however, due to mass, volume and 
shelf life, it is not feasible to include pre-prepared 
blood products in the payload. If blood products 
are to be administered, they will need to be 
donated by the other members of the crew. The 
concept of a “walking blood bank” has been 
practiced in combat zones by military 
organisations (60), and the stringent medical 
standards required of astronauts suggest that they 
may be a suitable population for this technique. 
For example, it is possible (though perhaps 
unlikely) that the entire crew are of the same, or 
compatible, blood types, able to donate to, and 
receive from, any other crew member. This has the 
advantage of a large potential donation pool if a 
massive transfusion is required, but has the 
possible disadvantage of limiting the potential pool 
of crew members. Alternatively, the crew could be 
allocated into compatible donor/recipient pairs, 
which would minimise the restriction on crew 
selection, but may reduce the amount of blood 
product available to the recipient.  
 
POSSIBLE ANAESTHESIA REGIMEN 
Before proposing a single anaesthetic regimen, it 
is worth highlighting that the anaesthetic regimen 
used will depend on the skill of the medical officer. 
If an emergency physician with specialist training 
is part of the crew, then they would be in the best 
position to decide on how to proceed. A single 
regimen will not be ideal in all situations. However, 
 
it may be necessary to specify a general regimen 
as a fall back if the physician is the patient. 
A single general anaesthetic regimen would 
simplify anaesthesia training and reduce cognitive 
burden on the crew performing the procedure 
before surgery. Dosages of medications should be 
calculated in advance for each crew member to 
minimise the risk of dose calculation, but it should 
be recognised that this is potentially fraught due to 
the unknown effect of physiological adaptations on 
pharmacology and pharmacokinetics.  
To return to the case, Dr FH requires intra-
abdominal surgery, which necessitates general 
anaesthesia with muscle relaxation. Dr FH’s 
weight before launch was 70kg, and pre-
calculated doses will be used. His current mass is 
unknown, and difficult to measure in the 
weightless environment! A possible anaesthesia 
regimen is proposed below: 
0 min: Gain IV/IO access. Premedication avoided 
as increases aspiration risk in RSI particularly if 
vomiting risk is high.  Preoxygenation with 100% 
O2 via mask. Attach monitoring equipment (non-
invasive BP, ECG, pulse oximetry). Implement the 
restraint system in preparation for surgery. 
5 min: Induction of anaesthesia with Ketamine 
150mg IV by slow push (2mg/kg) over 60 sec. 
Assess ease of ventilation by bag/mask.  
6 min: Muscle relaxation by Rocuronium 
1.2mg/kg. 
7 min: Intubation with an endotracheal tube (a half 
size smaller than would be required on earth, to 
account for oedema) by video laryngoscopy. 
Commence Ketamine maintenance infusion at 
10–45 micrograms/kg/minute, depending on 
response, using IV fluids generated on board.  
8 min: Commence surgery. Further doses of 
Rocuronium after 40-50 mins as required. 
Conclusion of surgery: Reversal of Rocuronium 
with Sugammadex 650mg IV (8mg/kg). 
Discontinue Ketamine infusion. Provide an initial 
dose of post-operative analgesia with Fentanyl, 
monitor Dr FH and extubate when appropriate. 
Further post-op pain relief could be given orally. 
 
CONCLUSION 
The capability to provide anaesthesia on an 
exploration mission to Mars will be essential to the 
successful completion of the mission. 
Physiological adaptations to microgravity may 
complicate any provision of anaesthesia. There 
are many challenges to this capability, arising from 
difficulties in providing and maintaining the 
required anaesthetic skill set (including airway 
management and regional anaesthesia), the 
logistical problem of providing enough 
consumables that will remain viable for the 
duration of the mission, and a lack of knowledge 
regarding any pharmacokinetic or 
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